Citations

Showing 10 of 108119 citations.

Penicillin in Syphilis . Joseph Earle Moore. Springfield, Ill.: Charles C. Thomas, 1947. Pp. x + 319. (Illustrated.) $5.00.
Kierland, Robert R.

Mayo Clinic

Science | October 8, 2021 | Volume: 105 | Issue: 2730 | Pages: 445-446

10.1126/science.105.2730.445-b Get It

Hepatic Artery Embolization for Palliation of Symptomatic Hypoglycemia in Patients With Hepatic Insulinoma Metastases
Linch, Forrest , Fleming, Chad J. , Vella, Adrian , Andrews, James C. , Thompson, Scott, Fleming, Chad, Vella, Adrian , Andrews, James , Linch, Forrest B , Thompson, Scott M.

Mayo Clinic

Journal of the Endocrine Society | October 7, 2021 | Volume: 5 | Issue: 12 | Pages: No page available

10.1210/jendso/bvab149 | PMID 34877442 Get It

Abstract Context Insulinoma is a pancreatic neuroendocrine tumor that causes hyperinsulinemic hypoglycemia. Symptomatic hypoglycemia related to hepatic insulinoma metastases may be addressed with liver-directed therapies such as hepatic artery embolization. Objective This work aimed to determine the safety and effectiveness of bland hepatic artery embolization (HAE) for palliation of symptomatic hypoglycemia in patients with hepatic insulinoma metastases refractory to medical management. Methods An institutional review board–approved retrospective review was undertaken of all patients with a tissue (n = 18) or imaging (n = 2) diagnosis of hepatic insulinoma metastases and symptomatic hyperinsulinemic hypoglycemia refractory to medical management who underwent bland HAE at a single center between January 1, 1998 and November 1, 2020. Twenty patients (10 women, 10 men; mean age, 56 years; range, 18-84 years) were identified who individually underwent 1 (n = 7), 2 (n = 5), 3 (n = 5), 4 (n = 2), or 5 (n = 1) HAEs, for an overall total of 45 HAEs. Post-HAE hypoglycemia recurrence was defined as onset of adrenergic symptoms (eg, sweating, weakness, tremor), neuroglycopenic symptoms (eg, confusion, loss of consciousness), and/or documented serum glucose of less than 50 mg/dL, in the absence of an alternative explanation. Median time to first hypoglycemia recurrence, hypoglycemia-free survival (HFS), and overall survival (OS) were calculated using Kaplan-Meier method. Results Before HAE, all patients experienced adrenergic or neuroglycopenic symptoms alleviated by glucose intake, and 60% (n = 12) of patients had documented serum glucose of less than 50 mg/dL within 1 week of the first treatment. Median post-HAE follow-up was 9.4 months (mean, 26 months; range, 0.1-190 months). Postprocedural hypoglycemic symptom relief after the first HAE was reported in 100% (n = 20) of patients before discharge or at follow-up. Post-HAE hypoglycemia recurrence occurred in 60% (n = 12) of patients with a median time to first hypoglycemia recurrence of 2 months (mean, 14 months; range, 0.2-60 months). After the first HAE, median HFS was 14.5 months, and median OS was 16 months. One patient experienced labile postprocedure blood glucose levels requiring intensive care unit admission for intravenous dextrose. Otherwise, no major procedure-related complications occurred. Conclusion Bland HAE is a safe, effective, and repeatable procedure for palliation of symptomatic hypoglycemia in patients with hepatic insulinoma metastases refractory to medical management.
Radioembolization for the Treatment of Hepatocellular Carcinoma: The Road to Personalized Dosimetry and Ablative Practice
Garza‐Ramos, Cynthia De la , Toskich, Beau B. , De la Garza-Ramos, Cynthia, De la Garza-Ramos, Cynthia

Mayo Clinic

Seminars in Interventional Radiology | October 7, 2021 | Volume: 38 | Issue: 04 | Pages: 466-471

10.1055/s-0041-1735571 | PMID 34629715 Get It

AbstractRadioembolization dosimetry for the treatment of hepatocellular carcinoma has evolved alongside our understanding of best practice for this therapy. At the core of advances in dosimetry are personalized and ablative applications of radioembolization, which have generated paradigm shifts in both safety and efficacy. This review provides a summary of fundamental radioembolization dosimetry concepts and narrates how our approach to treating patients has shifted from conventional to tailored and definitive therapy.
ACG Clinical Guidelines: Management of Benign Anorectal Disorders
Wald, Arnold , Bharucha, Adil E. , Limketkai, Berkeley N. , Malcolm, Allison , Whitehead, William E. , Zutshi, Massarat , Malcolm, Allison , Remes Troche, José M

Mayo Clinic

American Journal of Gastroenterology | October 7, 2021 | Volume: 116 | Issue: 10 | Pages: 1987-2008

10.14309/ajg.0000000000001507 | PMID 34618700 Get It

Benign anorectal disorders of structure and function are common in clinical practice. These guidelines summarize the preferred approach to the evaluation and management of defecation disorders, proctalgia syndromes, hemorrhoids, anal fissures, and fecal incontinence in adults and represent the official practice recommendations of the American College of Gastroenterology. The scientific evidence for these guidelines was assessed using the Grading of Recommendations Assessment, Development and Evaluation process. When the evidence was not appropriate for Grading of Recommendations Assessment, Development and Evaluation, we used expert consensus to develop key concept statements. These guidelines should be considered as preferred but are not the only approaches to these conditions.
A single‐institution retrospective study of causes of prolonged prothrombin time and activated partial thromboplastin time in the outpatient setting
Hazim, Antonious , Ruan, Gordon , Slusser, Joshua P. , Marshall, Ariela L. , Pruthi, Rajiv K. , Hazim, Antonious Z , Ruan, Gordon J , Pruthi, Rajiv K , Marshall, Ariela , Khodadadi, Ryan B.

Mayo Clinic

International Journal of Laboratory Hematology | October 7, 2021 | Volume: 44 | Issue: 1 | Pages: 209-215

10.1111/ijlh.13727 | PMID 34612006 Get It

AbstractIntroductionAn algorithmic approach, termed the prolonged clot time profile (PROCT), consisting of initial screening with prothrombin time (PT) and activated partial thromboplastin time (aPTT), reflexive mixing studies if indicated, and follow‐up assays depending on initial testing results, offers an efficient approach to delineate the etiology of a prolonged PT/aPTT. Herein, we present the outcomes of the PROCT in the outpatient setting.MethodsIn this retrospective study, we reviewed medical records of consecutive outpatients who had prolonged PT and/or aPTT noted in the routine coagulation laboratory and who had PROCT ordered in our institutional Special Coagulation Laboratory between 2010 and 2017.ResultsOne hundred and six patients, median age 55 years (IQR 30‐67), met our study criteria. Twenty‐nine patients had normal PT/aPTT, while 77 had persistent abnormalities and underwent reflexive testing. A prolonged PT, aPTT, or PT and aPTT was noted in 27 (35%), 27 (35%), and 23 (30%) respectively. Forty‐nine (64%) had an acquired condition, 17 (22%) had a congenital condition, 7 (9%) had unclear etiology, and 4 (5%) were the result of laboratory artifact. The most common known cause of an isolated prolonged PT in our study was vitamin K deficiency in 8 (10%), the most common cause of an isolated prolonged aPTT was lupus anticoagulant in 4 (5%), and the most common cause of prolonged PT and aPTT was liver disease in 11 (14%).ConclusionProlonged PT/aPTT have a wide range of causes, including artifactual prolongation or abnormalities in secondary hemostasis due to both inherited and acquired conditions.
Evaluation and Management of Acute Myelopathy
Sechi, Elia , Flanagan, Eoin P.

Mayo Clinic

Seminars in Neurology | October 7, 2021 | Volume: 41 | Issue: 05 | Pages: 511-529

10.1055/s-0041-1733792 | PMID 34619778 Get It

AbstractAcute myelopathies are spinal cord disorders characterized by a rapidly progressive course reaching nadir within hours to a few weeks that may result in severe disability. The multitude of underlying etiologies, complexities in confirming the diagnosis, and often unforgiving nature of spinal cord damage have always represented a challenge. Moreover, certain slowly progressive myelopathies may present acutely or show abrupt worsening in specific settings and thus further complicate the diagnostic workup. Awareness of the clinical and magnetic resonance imaging characteristics of different myelopathies and the specific settings where they occur is fundamental for a correct diagnosis. Neuroimaging helps distinguish compressive etiologies that may require urgent surgery from intrinsic etiologies that generally require medical treatment. Differentiation between various myelopathies is essential to establish timely and appropriate treatment and avoid harm from unnecessary procedures. This article reviews the contemporary spectrum of acute myelopathy etiologies and provides guidance for diagnosis and management.
The “Changing Landscapes” Special Edition
Lacy, Brian E. , Spiegel, Brennan , Spiegel, Brennan , Lacy, Brian E.

Mayo Clinic

American Journal of Gastroenterology | October 7, 2021 | Volume: 116 | Issue: 10 | Pages: 1969-1969

10.14309/ajg.0000000000001512 | PMID 34618694 Get It

Hinfp is a guardian of the somatic genome by repressing transposable elements
Nirala, Niraj K. , Li, Qi , Ghule, Prachi N. , Chen, Hsi‐Ju, Li, Rui , Zhu, Lihua Julie , Rice, Nicholas , Mao, Junhao , Stein, Janet L. , Wijnen, André J. van , Ip, Y. Tony , Rice, Nicholas P , Stein, Gary S , van Wijnen, Andre J , Ip, Y Tony , Wang, Ruijia , Stein, Gary S.

Mayo Clinic

Proceedings of the National Academy of Sciences | October 7, 2021 | Volume: 118 | Issue: 41 | Pages: No page available

10.1073/pnas.2100839118 | PMID 34620709 Get It

Significance Repression of the large number of transposable elements in eukaryotic genomes is essential for genome stability. The Piwi-interacting RNA and short interfering RNA pathways are critical for repressing transposable elements in germlines, but the repression of transposable elements in somatic tissues involves other components. While the mammalian Hinfp has been shown to regulate Histone4 and cell-cycle progression, our manuscript provides evidence that a function of the Drosophila Hinfp is to maintain Histone1 expression to repress most transposable elements in somatic genomes. This Hinfp–Histone1 axis provides a venue to study maintenance of genome stability and progression of pathological outcomes.
P077 Reliability of the Clinical Characterization of Isolated REM Sleep Behavior Disorder
Levendowski, Daniel J. , Lee‐Iannotti, Joyce , Guevarra, C, Timm, Paul, Angel, E, Mazeika, Gandis, Shprecher, David , Angel, Elise, Louis, Erik K. St.

Mayo Clinic

SLEEP Advances | October 7, 2021 | Volume: 2 | Issue: Supplement_1 | Pages: A46-A46

10.1093/sleepadvances/zpab014.121 Get It

Abstract Purpose Compare agreements between polysomnography-based (PSG) diagnosis of isolated REM-sleep-behavior-disorder (iRBD) and Non-REM-Hypertonia (NRH), a novel biomarker independently associated with synucleinopathy-related neurodegenerative diseases. Methods Sixteen patients with histories of dream-enactment-behavior (DEB)(women=38%; age:64.6±13.0) underwent PSG with simultaneously-recorded Sleep Profiler (SP). Two boarded sleep neurologists independently characterized iRBD. Physician1 combined abnormal qualitative REM-sleep-without-atonia (RSWA) by submental electromyography, with video-confirmation of probably DEB. Physician2 relied solely on qualitative RSWA. SP was auto-staged, technically reviewed, and reprocessed for automated abnormal NRH detection. Kappa scores measured physician and NRH agreements. Results In the 14 records with REM sleep, iRBD was characterized in: Physician1=64%, Physician2=79%, NRH=71% of the records. Across the three methods, unanimous iRBD agreement occurred in 57% of the records (positive=7, negative=1). The between-physician agreement in iRBD classifications was fair (kappa=0.32). The agreement between NRH and Physician1 was moderate (kappa=0.52) versus slight with Physician2 (kappa=0.05). NRH comparisons to consensus physician agreement yielded one false-positive and one false-negative iRBD finding. Physician2 classified: a) iRBD in two cases that were negative by Physician1 and NRH, and b) one negative case that Physician1 and NRH characterized as iRBD. Physician1 identified one negative case that was classified iRBD by Physician2 and NRH. Additionally, NRH was abnormal in one of the two records with no REM sleep. Discussion NRH may assist in iRBD risk assessment, given it agreed with at least one physician in 86% of the cases and the between-physician iRBD agreement was only fair. NRH also characterized iRBD-risk in patients with insufficient REM sleep for RSWA assessment.